Genmab — Januar 2020

[StockBull]

Ja det er nok det mest sandsynlige

[StockBull]

Men hvis alt er indenfor guiding så kommer der vel nødvendigvis IKKE en meddelelse ?

[Helge_LarsenPI-redaktør]

Jim Omel på Twitter: "I’ve yet to see a negative report on Dara. If it were oral (which it’s not), it should be in the drinking water of myeloma pts! Oh my"!https://conquer-magazine.com/ash-2019-mm-wrap-up?view=article&artid=1128:daratumumab-added-to-standard-therapy-longer-survival-in-newly-diagnosed-multiple-myeloma&utm_source=bronto&utm_medium=email&utm_term=Daratumumab+Added+to+Standard+Therapy+%3D+Longer+Survival+in+Newly+Diagnosed+Multiple+Myeloma&utm_content=The+Latest+in+Multiple+Myeloma

[JKY_VH]

Der må komme en meddelelse når milestonen udløses. Hvis ikke kommer der en nedjustering. Så en eller anden form for melding må der komme.

[Bulder]

Det er også min formodning. Vi får besked under alle omstændigheder.

[E_L]

@Bulder true, but the real comparison will be Dara SC vs Isa and then it will look much better

[Bulder]

Isa sc is on it's way as well

[StockBull]

Forestiller mig JNJ giver sig god tid til at informere hvis de skal af med milestonebetaling hvorimod hvis de 3 mia ikke er nået vil de meddele hurtigt

[StockBull]

Mener også de gav sig god tid til 2.5 mia milestone betalingen

[E_L]

but do we know yet if that will be an improvement vs IV for infections,
like Dara?

[Bulder]

I don't think sc is improving the matter of infections. It's infusion reactions. And I haven

[Bulder]

haven't seen anything on Isa sc.

[E_L]

yes, i was using indeed the wrong word

[Solsen]

https://pubs.acs.org/doi/pdf/10.1021/acsnano.9b08347# Måske noget spændende fra Genmabs medarbejdere. Desværre ikke tilgængelig i fuld version.

[E_L]

full version is here https://sci-hub.tw/https://pubs.acs.org/doi/pdf/10.1021/acsnano.9b08347#

[E_L]

another 'easy to read' article; good luck with it lol

[Solsen]

Thanks I will try

[Bulder]

Found this one: https://en.wikipedia.org/wiki/Oligomer

[Bulder]

I think it's about the clustering of antibodies under certain circumstances. The well known hexamers - which led to the hexabody - is one example. Oligomers are only different number of units in the cluster. Dimer is 2. Trimer is 3 and hexamer is 6.

[Bulder]

This mechanism - the forming of a cluster through the fc-part when the other end of the antibody (the fab-arms) binds to the antigen - is activating CDC reaction of the immune system. Thats how I understand it.